The sulfonamide functional group has exhibited its importance by its presence in a large variety of pharmaceuticals covering a wide range of biological activities. Potential pharmaceuticals that are designed to target the eicosanoid pathway of synthesis are of current interest. Examples of eicosanoids are prostaglandins, thromboxanes, and prostacyclins, which are responsible for pain and inflammation. Selectivity of isoenzymes is of particular importance for these potential pharmaceuticals. Cyclooxygenase (COX)-2 is the isoenzyme many of these potential pharmaceuticals are designed to inhibit. COX-2 is found in mast cells and is the key enzyme that converts arachidonic acid into prostaglandins. Failure of specificity for the COX-2 enzyme can lead to possible gastrointestinal toxic effects due to the inhibition of COX-1. 1-6 Celebrex, a diarylpyrazole, is one example of a diarylpyrazolebenzenesulfonamide that is currently in use and currently under study. 4, [7] [8] [9] [10] [11] Expanding the number of available benzenesulfonamides for testing to cyclopenta 
Scheme 1. Synthesis of 4-(1,4-diaryl-2H-cyclopent[d]pyridazin-2-yl)benzenesulfonamides.
Although historically the synthesis of 4-hydrazinobenzenesulfonamide•HCl, (1), has been through the diazotination of the corresponding amine and subsequent reduction via stannous chloride, 15 another route via the reaction of hydrazine with 4-chlorobenzenesulfonamide gave better and more consistent yields. The stable 4-hydrazinobenzenesulfonamide•HCl salt must be neutralized with hydroxide to form the free base (1a) before the ring closure will take place. The synthesis of precursor {(5Z)-5-[hydroxy(phenyl)methylene]cyclopenta-1,3-dien-1-yl}(phenyl)methanone (2), and {(5Z)-5-[hydroxy(4-methylphenyl)methylene]cyclopenta-1,3-dien-1-yl}(4-methylphenyl)methanone (3), have been previously reported by Linn and Sharkey. 16 The method of Linn and Sharkey using lithium cyclopentadienide and the corresponding acyl halide is convenient and yields of 75-85% are typically achieved although previously reported yields were about 35%. Traditional solvent combinations for the ring closure such as ethanol or ethanol/water were unsuccessful. The mixture of 4-hydrazinobenzenesulfonamide and compound (2) or (3) in refluxing methanol gave the product sulfonamide (4) or (5), respectively, in nearly quantitative yield. Full characterization of 3, 4 and 5 as well as crystal structures for (3) (see Figure 1 ) and (4) (see Figure 2) were obtained. Both exhibit the expected planar structures associated with 6-electron cyclopentadienyl, compound (3), or 10-electron bicyclic aromatic systems, compound (4) (see Table 2 ).
Discussion: Full analysis was performed on all compounds. Compound (3) shows a downfield singlet for the enol hydrogen at 18.3 ppm as expected. Compounds (4) and (5) both show complex aromatic regions in the 1 H NMR spectrum as expected because of the asymmetry. Para splitting was evident and resolved in both cases. 13 C NMR spectra were also obtained showing individual peaks for each chemically inequivalent carbon.
Infrared spectra showed the expected N-H and S=O stretches in the 3400-3600 cm -1 and 1350-1000 cm Crystal System, space group Monoclinic, P 2 1 /n Triclinic, P -1 Table 2 . Selected Bond Lengths (Å), Bond Angles (º) and Torsion Angles (º) for Compounds (3) and (4). Torsion Angle Torsion Angle In conclusion, the benzenesulfonamides (4) and (5) have been synthesized in good overall yield from the reaction of a suitable gamma diketone and a sulfonamide substituted arylhydrazine. 
4 Length Length
O(1)-C(1) 1.2762(18) N(1)-C(1) 1.366(3) O(2)-C(7) 1.2881(18) N(2)-C(7) 1.322(3) N(1)-C(20) 1.442(3) N(1)-N(2) 1.378(3) C(1)-C(2) 1.415(2) C(1)-C(2) 1.374(3) C(6)-C(7) 1.408(2) C(6)-C(7) 1.414(4) C(2)-C(6) 1.4645(19) C(2)-C(6) 1.458(3) C(2)-C(3) 1.409(2) C(2)-C(3) 1.417(4) C(3)-C(4) 1.390(2) C(C(2)-C(6)-C(7)-O(2) -11.0(2) C(2)-C(6)-C(7)-N(2) -3.8(4) O(1)-C(1)-C(2)-C(6) 5.0(2) N(1)-C(1)-C(2)-C(6) 0.9(4) C(2)-C(1)-C(15)-C(16) 51.3(2) C(2)-C(1)-C(14)-C(15) -56.5(3) C(6)-C(7)-C(8)-C(9) -38.6(2) C(6)-C(7)-C(8)-C(
EXPERIMENTAL

4-Hydrazinobenzenesulfonamide (1a)
Compound (1) (5.03 g, 22.5 mmol) was dissolved in a minimum amount of water (approx. 50 mL). The pH was adjusted to 8 with 2 M sodium hydroxide and 2 M HCl, if necessary, and a white solid precipitated. The mixture was vacuum-filtered and the resulting shiny, pearl-white solid was rinsed with ice-cold distilled water.
The product was dried in air for 24 h and 1a was recovered (2.77 g, 65.8%). The melting point was 158-159 ºC.
Hydroxyfulvene derivatives (2, 3)
General procedure: Freshly cracked cyclopentadiene (5.0 mL, 62 mmol) was added to a Schlenk flask containing approximately 100 mL dry ether at 0°C. n-Butyllithium (24 mL, 64 mmol) was added slowly and a white suspension formed. p-Toluoyl chloride (5.3 mL, 40 mmol) or benzoyl chloride (4.8 mL, 40 mmol) was added slowly via syringe. The solution was allowed to warm and stirred at rt for at least 45 min. A 10% acetic acid solution (100 mL) was added to quench the reaction and the mixture was extracted with ethyl ether. The organic layer was washed with water three times and dried with magnesium sulfate. The yellow solution was filtered and the ether removed on a rotary evaporator. Yields were consistently greater than 75%. Crystals for X-Ray diffraction were grown by slow evaporation from a saturated acetone solution. (4-methylphenyl)methylene]cyclopenta-1,3-dien-1-yl}(4-methylphenyl) 
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